Interaction of ochratoxin A with human serum albumin. Binding sites localized by competitive interactions with the native protein and its recombinant fragments

Chemico-Biological Interactions

Volumn 141, Issue 3, 2002, Pages 275-293

  Il'Ichev, Yuri V ^a   Perry, Jennifer L ^a   Rüker, Florian ^b   Dockal, Michael ^b   Simon, John D ^a,c  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF AGRICULTURAL SCIENCES   (Austria)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Binding site; Fluorescence polarization; Human serum albumin; Naproxen; Non steroidal anti inflammatory drug; Ochratoxin A; Preferential binding; Recombinant domains; Warfarin

Indexed keywords

ANION; ASPARTAME; BROMOPHENOL BLUE; HUMAN SERUM ALBUMIN; IBUPROFEN; LIGAND; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OCHRATOXIN; PHENYLALANINE; PHENYLBUTAZONE; PIROXICAM; RECOMBINANT PROTEIN; WARFARIN;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING COMPETITION; BINDING SITE; COMPLEX FORMATION; CONTROLLED STUDY; DEPOLARIZATION; DRUG BINDING SITE; DRUG PROTEIN BINDING; FLUORESCENCE SPECTROSCOPY; HUMAN; LIGAND BINDING; MOLECULAR INTERACTION; PROTEIN BINDING; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS;

ANIONS; BINDING, COMPETITIVE; FLUORESCENCE POLARIZATION; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAPROXEN; OCHRATOXINS; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SERUM ALBUMIN; WARFARIN;

EID: 0037145399     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(02)00078-9     Document Type: Article

References (89)

1. K.J. van der Merwe, P.S. Steyn, L. Fourie, Mycotoxins. Part II. The constitution of ochratoxins A, B, and C, metabolites of Aspergillus ochraceus Wilh., J. Chem. Soc. (1965) 7083-8.
2. Marquardt R.R., Frohlich A.A. A review of recent advances in understanding ochratoxicosis. J. Anim. Sci. 70:1992;3968-3988.
3. Pohland A.E., Nesheim S., Friedman L. Ochratoxin A: a review (technical report). Pure Appl. Chem. 64:1992;1029-1046.
4. Kuiper-Goodman T. Risk assessment of ochratoxin A: an update. Food Addit. Contam. 13:1996;53-57.
5. Chu F.S. Mycotoxins - food contamination, mechanism, carcinogenic potential and preventive measures. Mutat. Res. 259:1991;291-306.
6. Galvano F., Piva A., Ritieni A., Galvano G. Dietary strategies to counteract the effects of mycotoxins: a review. J. Food Prot. 64:2001;120-131.
7. Petzinger E., Ziegler K. Ochratoxin A from a toxicological perspective. J. Vet. Pharmacol. Ther. 23:2000;91-98.
8. Studer-Rohr I., Schlatter J., Dietrich D.R. Kinetic parameters and intraindividual fluctuations of ochratoxin A plasma levels in humans. Arch. Toxicol. 74:2000;499-510.
9. Krogh P. Role of ochratoxin in disease causation. Food Chem. Toxicol. 30:1992;213-224. and references therein.
10. Creppy E.E. Human ochratoxicosis. J. Toxicol.-Toxin Rev. 18:1999;277-293.
11. Gekle M., Sauvant C., Schwerdt G., Silbernagl S. Tubulotoxic mechanisms of ochratoxin A. Kidney Blood Pressure Res. 21:1998;277-279.
12. Simon P. Ochratoxin and kidney disease in the human. J. Toxicol.-Toxin Rev. 15:1996;239-249.
13. Steyn P.S., Stander M.A. Mycotoxins as causal factors of diseases in humans. J. Toxicol.-Toxin Rev. 18:1999;229-243.
14. Kumagai S., Aibara K. Intestinal absorption and secretion of ochratoxin A in the rat. Toxicol. Appl. Pharmacol. 64:1982;94-102.
15. Kumagai S. Ochratoxin A: plasma concentration and excretion into bile and urine in albumin-deficient rats. Food Chem. Toxicol. 23:1985;941-943.
16. Kumagai S. Effects of plasma ochratoxin A and luminal pH on the jejunal absorption of ochratoxin A in rats. Food Chem. Toxicol. 26:1988;753-758.
17. Hagelberg S., Hult K., Fuchs R. Toxicokinetics of ochratoxin A in several species and its plasma-binding properties. J. Appl. Toxicol. 9:1989;91-96.
18. Galtier P., Alvinerie M., Charpenteau J.L. The pharmacokinetic profiles of ochratoxin A in pigs, rabbits and chickens. Food Cosmet. Toxicol. 19:1981;735-738.
19. Li S., Marquardt R.R., Frohlich A.A., Vitti T.G., Crow G. Pharmacokinetics of ochratoxin A and its metabolites in rats. Toxicol. Appl. Pharmacol. 145:1997;82-90.
20. Chu F.S. Interaction of ochratoxin A with bovine serum albumin. Arch. Biochem. Biophys. 147:1971;359-366.
21. Uchiyama S., Saito Y. Protein-binding potential of ochratoxin A in vitro and its fluorescence enhancement. J. Food Hyg. Soc. Jpn. 28:1987;453-460.
22. Il'ichev Yu.V., Perry J.L., Simon J.D. Interaction of ochratoxin A with human serum albumin. preferential binding of the dianion and pH effects. J. Phys. Chem. B. 106:2002;452-459.
23. Palareti G., Legnani C. Warfarin withdrawal - pharmacokinetic-pharmacodynamic considerations. Clin. Pharmacokinet. 30:1996;300-313. and references therein.
24. Sudlow G., Birkett D.J., Wade D.N. The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 11:1975;824-832.
25. Petitpas I., Bhattacharya A.A., Twine S., East M., Curry S. Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J. Biol. Chem. 276:2001;22804-22809.
26. Il'ichev Yu.V., Perry J.L., Simon J.D. Interaction of ochratoxin A with human serum albumin. A common binding site of ochratoxin A and warfarin in subdomain IIA. J. Phys. Chem. B. 106:2002;460-465.
27. Dockal M., Carter D.C., Rüker F. The three recombinant domains of human serum albumin - structural characterization and ligand binding properties. J. Biol. Chem. 274:1999;29303-29310.
28. Dockal M., Chang M., Carter D.C., Rüker F. Five recombinant fragments of human serum albumin - tools for the characterization of the warfarin binding site. Protein Sci. 9:2000;1455-1465. and references therein.
29. Creppy E.E., Schlegel M., Röschenthaler R., Dirheimer G. Phenylalanine prevents acute poisoning by ochratoxin A in mice. Toxicol. Lett. 6:1980;77-80.
30. Baudrimont I., Murn M., Betbeder A.M., Guilcher J., Creppy E.E. Effect of piroxicam on the nephrotoxicity induced by ochratoxin A in rats. Toxicology. 95:1995;147-154.
31. Creppy E.E., Baudrimont I., Belmadani A., Betbeder A.M. Aspartame as a preventive agent of chronic toxic effects of ochratoxin A in experimental animals. J. Toxicol.-Toxin Rev. 15:1996;207-221.
32. Baudrimont I., Betbeder A.M., Creppy E.E. Reduction of the ochratoxin A-induced cytotoxicity in Vero cells by aspartame. Arch. Toxicol. 71:1997;290-298.
33. Mach H., Middaugh C.R., Lewis R.V. Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins. Anal. Biochem. 200:1992;74-80.
34. Nofsinger J.B., Simon J.D. Radiative relaxation of Sepia eumelanin is affected by aggregation. Photochem. Photobiol. 74:2001;31-37.
35. Lakowicz J.R. Principles of Fluorescence Spectroscopy. 2nd ed. 1999;291-300 Kluwer Academic/Plenum, New York.
36. Wei Y.J., Li K.A., Tong S.Y. The interaction of bromophenol blue with proteins in acidic solution. Talanta. 43:1996;1-10.
37. Trivedi V.D. On the role of lysine residues in the bromophenol blue-albumin interaction. Ital. J. Biochem. 46:1997;67-73.
38. Peters T. All about Albumin: Biochemistry, Genetics, and Medical Applications. 1996;76-131 Academic Press, San Diego.
39. He X.M., Carter D.C. Atomic structure and chemistry of human serum albumin. Nature. 358:1992;209-215.
40. Hashimoto S., Yabusaki T., Takeuchi H., Harada I. Structure and ligand-binding modes of human serum albumin studied by UV resonance Raman spectroscopy. Biospectroscopy. 1:1995;375-385.
41. Gekle M., Vogt R., Oberleithner H., Silbernagl S. The mycotoxin ochratoxin A deranges pH homeostasis in Madin Darby canine kidney cells. J. Membr. Biol. 139:1994;183-190.
42. Pesavento M., Profumo A. Interaction of serum albumin with a sulphonated azo dye in acidic solution. Talanta. 38:1991;1099-1106.
43. Porter D.J.T. Binding of 2-acetylpyridine-5-[(2-chloroanilino)thiocarbonyl]thiocarbono-hydrazone (Bw348u87) to human serum albumin. Biochem. Pharmacol. 44:1992;1417-1429.
44. Burke T.G., Mi Z.H. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal. Biochem. 212:1993;285-287.
45. Sebille B., Thuaud N., Tillement J.P. Study of binding of low-molecular-weight ligand to biological macromolecules by high-performance liquid-chromatography - evaluation of binding parameters for 2 drugs bound to human serum albumin. J. Chromatogr. 167:1978;159-170.
46. Wilting J., van der Giesen W.F., Janssen L.H.M., Weideman M.M., Otagiri M., Perrin J.H. The effect of albumin conformation on the binding of warfarin to human serum albumin - the dependence of the binding of warfarin to human-serum albumin on the hydrogen, calcium, and chloride-ion concentrations as studied by circular dichroism, fluorescence, and equilibrium dialysis. J. Biol. Chem. 255:1980;3032-3037.
47. Madsen B.W., Ellis G.M. Cooperative interaction of warfarin and phenylbutazone with human serum albumin. Biochem. Pharmacol. 30:1981;1169-1173.
48. Pinkerton T.C., Koeplinger K.A. Determination of warfarin-human serum albumin protein binding parameters by an improved Hummel-Dreyer high-performance liquid chromatographic method using internal surface reversed phase columns. Anal. Chem. 62:1990;2114-2122. and references therein.
49. Aki H., Yamamoto M. Thermodynamic characterization of drug-binding to human serum albumin by isothermal titration microcalorimetry. J. Pharm. Sci. 83:1994;1712-1716.
50. Zaton A.M.L., Ferrer J.M., Degordoa J.C.R., Marquinez M.A. Binding of coumarins to site I of human serum albumin. Effect of the fatty acids. Chem.-Biol. Interact. 97:1995;169-174.
51. Epps D.E., Raub T.J., Kezdy F.J. A general, wide-range spectrofluorometric method for measuring the site-specific affinities of drugs toward human serum albumin. Anal. Biochem. 227:1995;342-350.
52. Yamasaki K., Maruyama T., Kragh-Hansen U., Otagiri M. Characterization of site I on human serum albumin: concept about the structure of a drug binding site. Biochim. Biophys. Acta. 1295:1996;147-157.
53. Koizumi K., Ikeda C., Ito M., Suzuki J., Kinoshita T., Yasukawa K., Hanai T. Influence of glycosylation on the drug binding of human serum albumin. Biomed. Chromatogr. 12:1998;203-210. and references therein.
54. Parikh H.H., McElwain K., Balasubramanian V., Leung W., Wong D., Morris M.E., Ramanathan M. A rapid spectrofluorimetric technique for determining drug serum protein binding suitable for high-throughput screening. Pharm. Res. 17:2000;632-637.
55. Watanabe H., Kragh-Hansen U., Tanase S., Nakajou K., Mitarai M., Iwao Y., Maruyama T., Otagiri M. Conformational stability and warfarin-binding properties of human serum albumin studied by recombinant mutants. Biochem. J. 357:2001;269-274.
56. Villamor J.P., Zaton A.M.L. Data plotting of warfarin binding to human serum albumin. J. Biochem. Biophys. Methods. 48:2001;33-41.
57. Ishihama Y., Oda Y., Asakawa N. Microscale determination of dissociation constants of multivalent pharmaceuticals by capillary electrophoresis. J. Pharm. Sci. 83:1994;1500-1507. and references therein.
58. Chignell C. Optical studies of drug-protein complexes II. Interaction of phenylbutazone and its analogues with human serum albumin. Mol. Pharmacol. 5:1969;244-252.
59. Chignell C., Starkweather D.K. Species differences in the binding of phenylbutazone to plasma albumin. Pharmacology. 5:1971;235-244.
60. Maes V., Hoebeke J., Vercruysse A., Kanarek L. Optical studies into the nature of the high affinity binding site of human serum albumin for phenylbutazone. Mol. Pharmacol. 16:1979;147-153.
61. Elbary A.A., Vallner J.J., Whitworth C.W. Effect of albumin conformation on the binding of phenylbutazone and oxyphenbutazone to human serum albumin. J. Pharm. Sci. 71:1982;241-244.
62. Honoré B., Brodersen R. Albumin binding of anti-inflammatory drugs - utility of a site-oriented versus a stoichiometric analysis. Mol. Pharmacol. 25:1984;137-150.
63. Mohamed H.F., El-Bassiouni E., Shams-Eldeen M.A., Nasr M., Zeitoun R. Binding study of phenylbutazone and piroxicam to human serum albumin. IRCS Med. Sci.-Biochem. 14:1986;29-30.
64. Ascoli G., Bertucci C., Salvadori P. Stereospecific and competitive binding of drugs to human serum albumin: a difference circular dichroism approach. J. Pharm. Sci. 84:1995;737-741.
65. Caron G., Gaillard P., Carrupt P.-A., Testa B. Lipophilicity behavior of model and medicinal compounds containing a sulfide, sulfoxide, or sulfone moiety. Helv. Chim. Acta. 80:1997;449-462.
66. Fredericq E. Interactions de protéins et d'ions en solution. 1. Influences de structure dans les associations entre protéines et anions organiques. Bull. Soc. Chim. Belg. 63:1954;158-181.
67. Escolar D., Haro M.R., Saucedo A., Ayuso J., Jimenez A., Alvarez J.A. Determining acid equilibrium constants by means of chromatic parameters. Appl. Spectrosc. 50:1996;1290-1294.
68. Ho J.X., Holowachuk E.W., Norton E.J., Twigg P.D., Carter D.C. X-ray and primary structure of horse serum albumin (Equus caballus) at 0.27-nm resolution. Eur. J. Biochem. 215:1993;205-212.
69. Jakoby M.G. IV, Covey D.F., Cistola D.P. Localization of tolbutamide binding sites on human serum albumin using titration calorimetry and heteronuclear 2-D NMR. Biochemistry. 34:1995;8780-8787.
70. Aubry A.F., Markoglou N., McGann A. Comparison of drug binding interactions on human, rat and rabbit serum albumin using high-performance displacement chromatography. Comp. Biochem. Physiol. C. 112:1995;257-266.
71. a values determined by electrometric titration and ultraviolet absorption methods. Anal. Chem. 25:1954;726-727.
72. N.E. Kontaxis, C. Mitoma, Feasibility study for the use of iophenoxic acid as a reference marker for plasma proteins, NASA Contract Rep. 73032, 1966; Chem. Abstr. 66 (1967) 113778.
73. Mudge G.H., Desbiens N., Stibitz G.R. Binding of iophenoxate and iopanoate to human serum albumin. Drug Metab. Dispos. 6:1978;432-439.
74. R.C. Weast (Ed.), CRC Handbook of Chemistry and Physics, 64th ed., CRC Press, Boca Raton, FL, 1984, D-167.
75. Robertson A., Karp W. The effect of 2-hydroxybenzoylglycine on bilirubin albumin binding. Pharm. Toxicol. 63:1988;400-401.
76. Ashton J.M., Bolme P., Zerihun G. Protein binding of salicylic and salicyluric acid in serum from malnourished children: the influence of albumin, competitive binding and non-esterified fatty acids. J. Pharm. Pharmacol. 41:1989;474-480.
77. Mukherjee G.N., Sarkar S. Metal complexes of some peptide derivatives: Part V - complex formation of copper(II) with N-salicyloyl derivatives of some amino acids. Ind. J. Chem. 27A:1988;514-518.
78. Maheswaran M.M., Divakar S. Studies on the structure of the inclusion compound of β-cyclodextrin with aspartame. Ind. J. Chem. 30A:1991;30-34.
79. Oyekan A.O., Thomas W.O.A. The energetics of the interaction of piroxicam with plasma albumin. J. Pharm. Pharmacol. 36:1984;831-834.
80. Matsuyama K., Sen A.C., Perrin J.H. Binding of piroxicam to human serum albumin - effect of piroxicam on warfarin and diazepam binding. Pharm. Res. 4:1987;355-357.
81. Brée F., Urien S., Nguyen P., Riant P., Albengres E., Tillement J.P. A re-evaluation of the HSA-piroxicam interaction. Eur. J. Drug Metabol. Pharmacokinet. 15:1990;303-307.
82. Takács-Novák K., Tam K.Y. Multiwavelength spectrophotometric determination of acid dissociation constants. Part V: microconstants and tautomeric ratios of diprotic amphoteric drugs. J. Pharm. Biomed. Anal. 21:2000;1171-1182.
83. Whitlam J.B., Crooks M.J., Brown K.F., Pedersen P.V. Binding of non-steroidal anti-inflammatory agents to proteins. 1. Ibuprofen-serum albumin interaction. Biochem. Pharmacol. 28:1979;675-678.
84. Hage D.S., Noctor T.A.G., Wainer I.W. Characterization of the protein-binding of chiral drugs by high-performance affinity chromatography-Interactions of R- and S-ibuprofen with human serum-albumin. J. Chromatogr. A. 693:1995;23-32.
85. Sowell J., Mason J.C., Strekowski L., Patonay G. Binding constant determination of drugs toward subdomain IIIA of human serum albumin by near-infrared dye-displacement capillary electrophoresis. Electrophoresis. 22:2001;2512-2517.
86. Chiarini A., Tartarini A., Fini A. pH-Solubility relationship and partition coefficients for some anti-inflammatory arylaliphatic acids. Arch. Pharm. 317:1984;268-273.
87. Sollenne N.P., Means G.E. Characterization of a specific drug-binding site of human serum albumin. Mol. Pharmacol. 15:1979;754-757.
88. Kober A., Sjoholm I. Binding drugs to human serum albumin. 16. The binding-sites on human serum albumin for some non-steroidal anti-inflammatory drugs. Mol. Pharmacol. 18:1980;421-426.
89. Sugawara M., Takekuma Y., Yamada H., Kobayashi M., Iseki K., Miyazaki K. A general approach for the prediction of the intestinal absorption of drugs: regression analysis using the physicochemical properties and drug-membrane electrostatic interaction. J. Pharm. Sci. 87:1998;960-966.